# Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Eluting Stent Implantation

Study · id `cardio:ct-nct02494284` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02494284](<https://clinicaltrials.gov/study/NCT02494284>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02494284

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 364 participants.

## Technical summary

Registry record NCT02494284. Randomized; no masking; primary purpose treatment. Start 2015-12-22 (actual); primary completion 2017-02-13 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 364 participants (enrolled count; ClinicalTrials.gov record NCT02494284, source copy `cardio:ctgov-nct02494284-2017-02-23`, retrieved 2026-10-26)
- Started: 2015-12-22 (actual) (ClinicalTrials.gov record NCT02494284, source copy `cardio:ctgov-nct02494284-2017-02-23`, retrieved 2026-10-26)
- Primary completion: 2017-02-13 (actual) (ClinicalTrials.gov record NCT02494284, source copy `cardio:ctgov-nct02494284-2017-02-23`, retrieved 2026-10-26)
- Completion: 2017-02-13 (actual) (ClinicalTrials.gov record NCT02494284, source copy `cardio:ctgov-nct02494284-2017-02-23`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02494284, source copy `cardio:ctgov-nct02494284-2017-02-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02494284-2017-02-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Eluting Stent Implantation
- Acronym: STAMP-DES
- Condition: Coronary Artery Disease
- Intervention (Drug): Clopidogrel
- Intervention (Drug): Aspirin plus clopidogrel
- Lead sponsor: CHEOL WHAN LEE, M.D., Ph.D
- Lead sponsor class: OTHER
- Collaborator: CardioVascular Research Foundation, Korea
- Collaborator class: OTHER
- Collaborator: Medtronic
- Collaborator class: INDUSTRY
- Collaborator: Chong Kun Dang Pharmaceutical Corp.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry lists this organization as the lead sponsor: CHEOL WHAN LEE, M.D., Ph.D (`cardio:org-cheol-whan-lee-m-d-ph-d`)
- Registry lists this organization as a collaborator: CardioVascular Research Foundation, Korea (`cardio:org-cardiovascular-research-foundation-korea`)
- Registry lists this organization as a collaborator: Medtronic (`cardio:medtronic`)
- Registry lists this organization as a collaborator: Chong Kun Dang Pharmaceutical Corp. (`cardio:org-chong-kun-dang-pharmaceutical-corp`)

## Provenance

Content hash: 9a6eab178b502791673351db9ae3c8a7c9558c7531686a8adcfedc341dabeefe
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
